title: Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility.
abstract: BACKGROUND
  A system was established to examine the extent to which the apheresis donor determines platelet recovery after transfusion, to measure the impact of ABO identity, and to predict outcome by evaluating the donor.
  
  
  METHODS
  The percentage of platelet recovery was measured after prophylactic transfusion of apheresis units divided from single donors to paired recipients with uncomplicated thrombocytopenia secondary to leukemia chemotherapy. Platelet microaggregation induced by citrate was measured at the time of apheresis.
  
  
  RESULTS
  Platelet recoveries in paired recipients correlated strongly when both transfusions were ABO- identical. When one recipient was ABO-identical and the other was ABO-nonidentical, nonidentical transfusions yielded one-third the recovery of ABO-identical transfusions. In ABO-identical transfusions, platelet recovery in donors having microaggregates in the before-apheresis ACD sample was one-third that in donors without microaggregates. This difference was observed at 1 and 24 hours. Expression of P-selectin in the apheresis units at the time of transfusion correlated well with ACD microaggregates in the before-apheresis sample.
  
  
  CONCLUSIONS
  When transfusions of platelets are ABO-identical, donor quality dominates recovery in circulation. Donor quality is predicted by a rapid and simple assay of citrate-induced microaggregation performed at the time of apheresis. When donor quality is factored out, ABO identity prevails.
authors.affiliation: Section of Hematology Research, Division of Transfusion Medicine and Department of Biochemistry and Molecular Biology, Mayo Clinics and Foundation, Rochester, Minnesota 55905, USA.
authors.forename: Teresa M
authors.initials: TM
authors.lastname: Jiménez
authors.forename: Sachin B
authors.initials: SB
authors.lastname: Patel
authors.forename: Alvaro A
authors.initials: AA
authors.lastname: Pineda
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
authors.forename: Whyte G
authors.initials: WG
authors.lastname: Owen
mesh_terms: D000017:ABO Blood-Group System; D000925:Anticoagulants; D000970:Antineoplastic Agents / Q000009:adverse effects; D001781:Blood Component Removal; D001782:Blood Donors; D001788:Blood Grouping and Crossmatching; D019343:Citric Acid; D004492:Edetic Acid; D005260:Female; D005434:Flow Cytometry; D005947:Glucose / Q000031:analogs & derivatives*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D019007:P-Selectin / Q000097:blood; D010974:Platelet Aggregation; D010976:Platelet Count; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy; D013997:Time Factors
chemical_list: D000017:ABO Blood-Group System; D000925:Anticoagulants; D000970:Antineoplastic Agents; D019007:P-Selectin; C002113:acid citrate dextrose; D019343:Citric Acid; D004492:Edetic Acid; D005947:Glucose